An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia

Blood

Volumn 117, Issue 13, 2011, Pages 3505-3513

  Danese, Mark D ^a   Griffiths, Robert I ^a,b   Gleeson, Michelle ^a   Satram Hoang, Sacha ^c   Knopf, Kevin ^d   Mikhael, Joseph ^e   Reyes, Carolina ^c,f  

^a Outcomes Insight Inc   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GENENTECH INC   (United States)

^d CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; FLUDARABINE; RITUXIMAB;

AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; MONOTHERAPY; NEUTROPENIA; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RISK REDUCTION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 79953710007     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-08-301929     Document Type: Article

References (45)

1. Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet. 2008;371(9617):1017-1029. (Pubitemid 351389535)
2. CLL Trialists' Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J Natl Cancer Inst. 1999;91(10):861-868.
3. National Comprehensive Cancer Network. Non- Hodgkin's Lymphomas: NCCN Clinical Practice Guidelines in Oncology v. 1.2010. Fort Washington, PA: NCCN; 2010. http://www.jnccn.org/content/8/3/288.full.pdf+html. Accessed April 8, 2010.
4. Hallek M, Fischer K, Fingerle-Rowson G, et al. The addition of rituximab to fludarabine and cyclophosphamide improves the overall survival of patients with chronic lymphocytic leukemia. Lancet. 2010;376:1164-1174.
5. Hallek M, Fingerle-Rowson G, Fink A-M, et al. First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the German CLL study group [abstract]. Blood. 2009;114:223. Abstract 535.
6. Genentech, Inc. Rituximab prescribing information, revised February 2010. http://www.gene.com/gene/products/information/pdf/rituxanprescribing.pdf. Accessed August 1, 2010.
7. Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence-SEER 17 Regs Limited-Use + Hurricane Katrina Impacted Louisiana Cases, Nov 2009 Sub (1973-2007 various)-Linked To County Attributes- Total U.S., 1969-2007 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2010, based on the November 2009 submission. http:www.seer.cancer.gov. Accessed June 15, 2010.
8. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(suppl 8):3-18.
9. Surveillance Epidemiology and End Results. SEER Data, 1973-2006. Bethesda, MD: Surveillance Research Program, National Cancer Institute; 2007. http://seer.cancer.gov/about. Accessed March 15, 2010.
10. National Cancer Institute. SEER-Medicare: How the SEER & Medicare data are linked. Bethesda, MD: National Cancer Institute; 2007. http://healthservices.cancer.gov/seermedicare/overview/linked.html. Accessed August 1, 2010.
11. Practice Management Information Corporation. ICD-9-CM. 6th ed. Los Angeles, CA: Practice Management Information Corporation; 2005.
12. Practice Management Information Corporation. HCPCS. Los Angeles, CA: Practice Management Information Corporation; 2005.
13. Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002;40(suppl 8):55-61.
14. Fritz A, Ries L, eds. SEER Program Code Manual. 3rd ed. Bethesda, MD: National Cancer Institute; 1998.
15. Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA, eds. SEER Summary Staging Manual-2000: Codes and Coding Instructions (NIH publication no. 01-4969). Bethesda, MD: National Cancer Institute; 2001.
16. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53(12):1258-1267. (Pubitemid 32007842)
17. National Cancer Institute. SAS Macro to Remove Unreliable Diagnosis Coding. Bethesda, MD: National Cancer Institute; 2010.
18. National Cancer Institute. SAS Macro to Calculate a Comorbidity Index for a Patient With Respect to Cancer. Bethesda, MD: National Cancer Institute; 2010.
19. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40(5):373-383. (Pubitemid 17055592)
20. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
21. Romano PS, Roos LL, Luft HS, Jollis JG, Doliszny K. A comparison of administrative versus clinical data: coronary artery bypass surgery as an example. J Clin Epidemiol. 1994;47(3):249-260. (Pubitemid 24109737)
22. Healthcare Cost and Utilization Project. Overview of the Clinical Classifications Software (CCS) for ICD-9-CM. Rockville, MD: Agency for Healthcare Research and Quality; 2009.
23. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167(4):492-499.
24. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York, NY: Springer-Verlag; 2000.
25. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127(8):757-763. (Pubitemid 27446562)
26. Stürmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol. 2006;59(5):437-447.
27. Stürmer T, Schneeweiss S, Brookhart MA, Rothman KJ, Avorn J, Glynn RJ. Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am. J. Epidemiol. 2005;161(9):891-898. (Pubitemid 40577844)
28. Stürmer T, Rothman KJ, Avorn J, Glynn RJ. Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution - a simulation study. Am J Epidemiol. 2010;172(7):843-854.
29. Hosmer DW, Lemeshow S. Applied Logistic Regression. Hoboken, NJ: Wiley; 1989.
30. Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112(4):975-980.
31. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4079-4088. (Pubitemid 46211313)
32. Brenner H, Gondos A, Pulte D. Trends in longterm survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. Blood. 2008;111(10):4916-4912.
33. Kristinsson SY, Dickman PW, Wilson WH, Caporaso N, Björkholm M, Landgren O. Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11 179 patients diagnosed between 1973-2003 in Sweden. Haematologica. 2009;94(9):1259-1265.
34. Abrisqueta P, Pereira A, Rozman C, et al. Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience. Blood. 2009;114(10):2044-2050.
35. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol. 2001;19(8):2153-2164. (Pubitemid 32366969)
36. Huhn D, von Schilling C, Wilhelm M, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood. 2001;98(5):1326-1331.
37. Wierda WG. Current and investigational therapies for patients with CLL. Hematology Am Soc Hematol Educ Program. 2006;285-294.
38. Keating GM. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs. 2010;70(11):1445-1476.
39. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs. 2003;63(8):803-843. (Pubitemid 36432084)
40. Curtis E, Quale C, Haggstrom D, Smith-Bindman R. Racial and ethnic differences in breast cancer survival: how much is explained by screening, tumor severity, biology, treatment, comorbidities, and demographics? Cancer. 2008;112:171-180.
41. Wang M, Burau KD, Fang S, Wang H, Du XL. Ethnic variations in diagnosis, treatment, socioeconomic status, and survival in a large population-based cohort of elderly patients with non-Hodgkin lymphoma. Cancer. 2008;113:3231-3241.
42. Baicker K, Chandra A, Skinner JS, Wennberg JE. Who you are and where you live: how race and geography affect the treatment of Medicare beneficiaries. Health Aff (Millwood). 2004;(suppl Web Exclusives):VAR33-44.
43. Groeneveld PW, Laufer SB, Garber AM. Technology diffusion, hospital variation, and racial disparities among elderly Medicare beneficiaries: 1989-2000. Med Care. 2005;43(4):320-329.
44. Shah BR, Laupacis A, Hux JE, Austin PC. Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review. J Clin Epidemiol. 2005;58(6):550-559. (Pubitemid 40692720)
45. Hadley J, Yabroff KR, Barrett MJ, Penson DF, Saigal CS, Potosky AL. Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. J Natl Cancer Inst. 2010;102(23):1780-1793.